Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Composite for enhancing transdermal administration and application thereof

A transdermal drug delivery and composition technology, applied in the field of drug delivery, can solve the problems of ineffective promotion of macromolecules such as protein drug transdermal, skin allergies, low efficiency, etc., and achieve the effect of improving the efficiency of transdermal delivery

Active Publication Date: 2013-03-06
FUJIAN LONGSHENG BIOLOGICAL TECH CO LTD
View PDF20 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, they have two major disadvantages: easy to cause skin allergies and unable to effectively promote the transdermal penetration of macromolecules such as protein drugs
[0007] Compared with the high efficiency of intravenous injection and oral administration, transdermal drug delivery has many advantages, but the low efficiency is always the bottleneck of this new drug delivery method

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composite for enhancing transdermal administration and application thereof
  • Composite for enhancing transdermal administration and application thereof
  • Composite for enhancing transdermal administration and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0046] Example 1 Comparison of TD-1-EGF and TD-1-EGF+ATP Transdermal Drugs

[0047] TD-1 is a short peptide of ACSSSPSKHCG; EGF is epidermal growth factor (ATP helps TD-1 to mediate the fusion transdermal protein drug transdermal in this application, taking human epidermal growth factor TD-1-huEGF as an example, huEGF uses EGF in the following text express).

[0048] TD-1-EGF comes from the nanobiology laboratory of University of Science and Technology of China to construct recombinant plasmids, and use the Escherichia coli prokaryotic expression system to express and purify the target protein. The brief description is as follows: by using pFN18A halotag 7 Flexi vector (Promega Company), the recombinant plasmid was constructed, and then transformed into KRX competent cells (Promega Company), glucose and rhamnose (Promega Company) were induced to express the target protein at 25°C and 220rpm, After 20 hours, the bacterial cells were collected and crushed, and the target protei...

Embodiment 2

[0057] Example 2 Comparison of TD-1+IFN-α-2b and TD-1+ATP+IFN-α-2b Transdermal Drugs

[0058] TD-1 is a short peptide of ACSSSPSKHCG; IFN-α-2b is a human alpha interferon-2b subtype (in this application, ATP helps TD-1 to help protein drugs transdermal with human alpha interferon-2b subtype in a mixed administration mode For example, hu-IFN-α-2b is represented by IFN in the following text).

[0059] TD-1 was obtained from Shanghai Jill Biochemical Co., Ltd. (GLS), IFN was obtained from Anke Bioengineering Technology Co., Ltd. (Anke-Bio), and adenosine triphosphate (ATP) was purchased from BioBasic Inc., Canada (Product No. AB0020).

[0060] IFN is a proven antiviral and protein drug. In this example, during the transdermal administration of the protein drug IFN mediated by TD-1, adenosine triphosphate (ATP), a biological direct energy supply substance, was applied at the same time to study the effect of ATP on Effect of the protein drug IFN on the transdermal efficiency media...

Embodiment 3

[0067] Embodiment 3 The relationship between the transdermal efficiency of TD-1-EGF and the dose of ATP

[0068] During the transdermal administration of the TD-1-mediated transdermal fusion protein drug TD-1-EGF, different doses (0mM-20mM) of adenosine triphosphate --- ATP, a biological direct energy supply substance, were applied simultaneously to detect the transdermal fusion protein The relationship between the transdermal efficiency of the drug TD-1-EGF and the dose of ATP.

[0069] Abdominal skin tissues of intact SD rats were taken, and placed in physiological saline (0.9% Nacl aqueous solution) after hair removal for use.

[0070] Preparation of transdermal drugs, the method is as follows: the fusion protein TD-1-EGF (stock solution concentration 1mg / mL) with a purity of more than 95% is drawn with a Gilson pipette (Gilson, France) 50 μL (corresponding to the amount of fusion protein is 50 μg), diluted to 500 μL with normal saline, that is, the concentration of 100 tr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an application of a composite for enhancing transdermal administration, a method for enhancing transdermal administration of drug, application of adenosine triphosphate and a medicine containing a transdermal composite. In the invention, by the increase of the supply of ATP (adenosine triphosphate) in transport process of a transdermal drug mediated with transdermal enhancing peptide, the transport capacity of the transdermal drug mediated with the transdermal enhancing peptide can be obviously improved.

Description

technical field [0001] The invention belongs to the field of drug delivery, in particular, it relates to a composition for enhancing transdermal drug delivery and its application. Background technique [0002] Drug delivery is the technical basis of clinical treatment, and the efficiency of drug delivery will directly affect the effect of clinical treatment of various diseases. At present, the conventional routes of drug delivery mainly include systemic administration represented by intravenous injection and oral administration, and local administration represented by subcutaneous, intradermal and intramuscular injection. However, these traditional drug administration methods will bring many inconveniences to patients, such as injection dermatitis, gastrointestinal systemic toxicity, and adverse reactions caused by long-term systemic administration of large doses. The emergence of transdermal drug delivery provides a safer and more reliable transportation route for various ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K47/42A61K47/48A61K38/18A61K38/21A61K47/26
Inventor 温龙平张力汪昌丽阮仁全王姗姗魏鹏飞金佩佩万小妹
Owner FUJIAN LONGSHENG BIOLOGICAL TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com